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MGMT-TRANSDUCED gd T CELLS FUNCTION IN THE PRESENCE OF
TEMOZOLAMIDE AND SHOW ENHANCED CYTOTOXICITY AGAINST
TEMOZOLOMIDE-RESISTANT HIGH GRADE GLIOMA CELL LINES:
POTENTIAL STRATEGIES FOR COMBINATION OF CHEMOTHERAPY AND
IMMUNOTHERAPY
Lamb, L.S.1, Bowersock, J.1, Dasgupta, A.2, Gillespie, G.Y.1,
Spencer, H.T.2 1University of Alabama at Birmingham School of Medi-
cine, Birmingham, AL; 2Emory University School of Medicine, Atlanta,
GA
Treatment strategies for high-grade primary brain tumors such as
glioblastomamultiforme (GBM) have failed to significantly and con-
sistently extend survival. Recently, several studies have suggested that
chemotherapy-induced tumor stress may increase tumor vulnerabil-
ity to the immune reaponse. We have previously shown that ex-
panded/activated gd T cells from healthy donors recognize
NKG2D ligands expressed on malignant glioma and are cytotoxic
to glioma cell lines, primaryGBMexplants, and human glioma intra-
cranial cell line xenografts placed in immunodeficient mice. In this
report, we show standard therapies forGBMbased on temozolomide
(TMZ) increase the expression of stress-associated NKG2D ligands
on TMZ-resistant glioma cells, potentially rendering them vulnera-
ble to attack by gdT cells. As TMZ is also highly toxic to gdT cells,
we genetically modified gdT cells in culture using a lentiviral vector
encoding P140KMGMT, resulting in resistance to TMZ at concen-
trations up to 400mM.Geneticmodification ofgdTcells did not alter
their phenotype or their ability to kill targets, as both non-modified
and gene-modified gdT cells were highly cytotoxic to U87 cells and
TMZ-resistant clones of SNB-19 (SNB-19TMZ-R) and U373
(U373TMZ-R) glioma cell lines in the presence of up to 400 mM
TMZ. Importantly, gene modified gd T cells showed greater cyto-
toxicity to both U373TMZ-R and SNB-19TMZ-R cultures in the pres-
ence of TMZ, suggesting that TMZ exposed more targets to gd T
cell lysis. These findings demonstrate that TMZ resistant gd T cells
can be generated without impairing cellular functions, and the genet-
ically modified cells efficiently kill TMZ-resistant human glioma cell
lines in the presence of high concentrations of TMZ. These results
provide a mechanistic basis for combining and timing chemotherapy
and drug resistant cellular immunotherapy to treat GBM.
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PHASE I/II STUDY OF INTRAVENOUS PLERIXAFOR ADDED TO A MOBILI-
ZATION REGIMEN OF G-CSF IN LYMPHOMA PATIENTS UNDERGOING
AUTOLOGOUS STEM CELL COLLECTION
Cashen, A.1, Rettig, M.1, Gao, F.2, Reineck, T.1, Abboud, C.1, Stockerl-
Goldstein, K.1, Vij, R.1, Uy,G.1,Westervelt, P.1, DiPersio, J.1 1Washington
University School of Medicine, St. Louis, MO; 2Washington University
School of Medicine, St. Louis, MO
Background: In Phase II and III trials, plerixafor has been combined
with G-CSF and administered as a subcutaneous injection of 0.24
mg/kg, given 9-11 hours before pheresis. Intravenous (IV) adminis-
tration of plerixafor may result in a faster rise and higher peak in the
peripheral CD34+ cell count, allowing administration of plerixafor
the same day as pheresis and improving stem cell collection.
Methods:The primary objectives of this Phase I/II studywere to de-
termine the MTD of IV plerixafor, up to 0.40 mg/kg combined with
G-CSF, and the efficacy of IV plerixafor + G-CSF to mobilize$ 2 x
106 CD34+ cells/kg from pts. with lymphoma. Pts. started mobiliza-
tion with G-CSF (10 ug/kg SC daily) on days -4 thru -1 and on each
day of pheresis (up to 4 pheresis days). IV plerixafor was given over
30 min. 4 hrs. before each pheresis, beginning day 0.
Results: 46 pts. (median age, 53; 31 NHL/15HL) have been treated
to date. In Phase I, 25 pts. were treated with IV plerixafor at escalat-
ing doses (10 pts. at 0.16 mg/kg, 3 at 0.24 mg/kg, 6 at 0.32 mg/kg,
and 6 at 0.40 mg/kg). One dose-limiting toxicity (grade 2 chestpain) was observed at 0.32 mg/kg. In Phase II, an additional 21
pts. have been treated at 0.40 mg/kg. No grade 3/4 toxicities attrib-
uted to plerixafor occurred in any pt. treated at 0.40 mg/kg. Overall,
44 of 46 pts. (96%, 80%CI 89-99%)met the goal collection of$ 2.0
x 106 CD34+ cells/kg, and 37 of 46 pts. (80%, 80% CI 71-88%) col-
lected$ 5.0 x 106 CD34+ cells/kg, in a median 2 days of pheresis. 20
of 27 pts. (74%, 80% CI 60-85%) treated with 0.40 mg/kg collected
$ 2.0 x 106 CD34+ cells/kg in 1 day of pheresis. In transplanted pts.,
there has been no delay in engraftment. Analysis of CD34+ hemato-
poietic stem and progenitor cells (HSPCs) revealed that G-CSFmo-
bilized grafts were enriched with CD45RA-CD123+/- primitive
HSPCs while plerixafor preferentially mobilized CD34dimC-
D45RA+CD123hi plasmacytoid dendritic cell precursors and
CD34+CD45RA-CD123hi cells. Flow cytometric analyses showed
that the CD34+ subsets preferentially mobilized by plerixafor ex-
pressed high levels of cell surface CXCR4.
Conclusions: Plerixafor IV, at doses up to 0.40 mg/kg, is well-toler-
ated and effective when added toG-CSF for themobilization of stem
cells from pts. with lymphoma, with mobilization kinetics and stem
cell collections that compare favorably with sc dosing. In addition,
our data suggest that G-CSF and plerixafor mobilize distinct subsets
of human CD34+ HSPCs.
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COMPLEX KARYOTYPE (CK) IS ASSOCIATEDWITH INCREASED CUMULA-
TIVE INCIDENCE OF RELAPSE (CIR) FOLLOWING AUTOLOGOUS STEM
CELL TRANSPLANTATION (ASCT) FOR MANTLE CELL LYMPHOMA
(MCL) IN FIRST REMISSION
Cohen, J.B.1, Ruppert, A.S.1, Kaplan, L.D.2, Baiocchi, R.1, Porcu, P.1,
Flynn, J.1, Penza, S.1, Jones, J.A.1, Blum, K.A.1, Devine, S.M.1,
Andritsos, L.A.1 1The Ohio State University- James Cancer Center, Co-
lumbus, OH; 2University of California, San Francisco, San Francisco, CA
Introduction: Complex cytogenetics predict patient outcomes and
response to therapy in many hematologic malignancies, but there
are few data regarding their significance in patients undergoing
ASCT in MCL.
Methods: Patients undergoing ASCT for MCL at the Ohio State
University in first remission with $ 3 chromosomal abnormalities
were considered complex. Cumulative incidence of relapse (CIR)
was measured from the date of transplant until the date of relapse,
censoring relapse-free patients at last follow-up. Death without re-
lapse (n 5 1) was treated as a competing risk event. Gray’s test was
used to evaluate differences in CIR.
Results: Of 37 patients, 78% were male. At diagnosis, median age
was 60 (range 37 to 74), 89% had bone marrow involvement, and
all were stage IV. ThemedianMIPIwas 5.9 (range 4.8 to 8.1). Induc-
tion regimens includedR-M-CHOP (n5 27), R-CHOP (n5 8), and
R-HyperCVAD (n5 2). Mobilization regimens included etoposide,
cytarabine, rituximab (EAR) (n 5 28), GCSF (n 5 2), GCSF with
plerixafor (n 5 4), cyclophosphamide (n 5 2), and etoposide (n 5
1). Conditioning regimens included BEAM (n 5 17), BEC (n 5
19), and busulfan, cyclophosphamide, and etoposide (n 5 1). Thir-
teen patients had complex cytogenetics (35%), including 4 with de-
letion of 17p. Complex patients were more likely to have an ECOG
PS$ 2 (p5 0.03), and higher median LDH at diagnosis (p5 0.01),
with no large differences in MIPI, age, sex, induction regimen, and
response to induction (p.0.20). Complex patients had a median
time to relapse of 14.8 months versus median not reached in the
non-complex group (HR 8.30, 95% CI 2.24 – 30.80, p 5 0.002). 3
of 4 complex patients with deletion 17p relapsed within 15 months
with 1 death at 5 months, but the time to relapse was still shorter
in remaining complex patients (p 5 0.01). The induction regimen
R-M-CHOP largely coincided with EAR and was associated with
longerCIR (p5 0.007) while response,MIPI, conditioning regimen,
age, sex, performance status, and LDH were not (p.0.20).
Conclusion: A complex karyotype predicts for a shorter time to re-
lapse in MCL patients undergoing ASCT in first remission. In addi-
tion, patients who received R-M-CHOP (all but 1 mobilized with
EAR) had prolonged time to relapse. Although complex patientsS205
